Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
All content for Beginner's Mind is the property of Christian Soschner and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
EP 158 - Rafael Rosengarten: Why 90% of Cancer Drugs Fail — and the Radical AI Fix You’ve Never Heard Of
Beginner's Mind
2 hours
8 months ago
EP 158 - Rafael Rosengarten: Why 90% of Cancer Drugs Fail — and the Radical AI Fix You’ve Never Heard Of
Most cancer drugs fail. Not because the science is wrong—because we’re solving the wrong problems. The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there’s no second chance. Behind the headlines of “precision medicine,” there’s a deeper story nobody’s telling. Until now. 🎯 Enter Rafael Rosengarten, the scientist-turned-founder who’s rewriting the rules of drug development. In this gripping conversation, we unpack how RNA, AI, and deep empathy c...
Beginner's Mind
Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
